Across three days in Lisbon, PTMC 2026 brought together healthcare professionals, patients, policymakers, producers, investors and technology providers for a wide-ranging programme focused on the future of medicinal cannabis. From practical clinical education and patient experience to cultivation innovation, post-harvest quality, business resilience and political reform, the conference reflected a sector that is becoming more mature, more evidence-led and more commercially sophisticated.
The event opened with sessions designed to ground the conversation in the realities of clinical practice and patient access. A dedicated educational workshop gave accredited healthcare professionals a practical introduction to the endocannabinoid system, cannabinoid pharmacology, prescribing considerations, dosing principles, patient selection and safety. Alongside this, an open consultation session created space for patients, caregivers, advocates and professionals to discuss lived experience, information gaps and the challenges families continue to face when seeking trusted guidance.
Networking began before the main conference programme, with delegates gathering at TOPO Martim Moniz for a Welcome Cocktail overlooking São Jorge Castle and Lisbon’s historic skyline. The relaxed rooftop setting offered an informal opportunity to reconnect with colleagues, meet new contacts and begin conversations that continued throughout the event.
Seven years after medicinal cannabis became legally available in Portugal, the opening session examined the country’s progress, achievements and remaining challenges. Institutional representatives and key stakeholders reflected on the current regulatory and clinical landscape, the evolution of patient access, research and industry, and the priorities that will shape Portugal’s role in the international medicinal cannabis market.
As the industry enters a more competitive phase, speakers explored what it takes to build investable, scalable and financially sustainable cannabis companies. Discussions moved beyond access to capital to consider operational efficiency, supply chain optimisation, capital allocation, investment strategy and business models capable of creating long-term value in an increasingly price-sensitive global market.
Operational excellence was a recurring theme throughout the programme. Sessions considered how producers can improve margins, consistency and resilience through better systems, smarter infrastructure and more integrated approaches to cultivation. Automation, environmental control, data integration, lighting, traceability and connected software platforms all featured as part of a broader conversation about the next generation of medicinal cannabis operations.
Contributors including Medi Plant Supplies, Quest Climate, ProGuard, Growlink, CANNA AGRI, Hagra and Softrim helped illustrate how specialist technologies are supporting regulated producers. Their contributions highlighted the importance of climate management, biosecurity, irrigation, nutrition, automation, water efficiency, traceability and post-harvest handling in delivering consistent, compliant, high-quality medicinal cannabis at scale.
A keynote from long-standing cannabis reform advocate Alex Rogers brought an international perspective to the programme. Drawing on more than three decades of involvement in medical cannabis reform and patient rights campaigns, Rogers reflected on policy modernisation efforts across the United States and Europe, and on the role of advocacy in shaping access, regulation and the development of the global medicinal cannabis industry.
The programme also placed a spotlight on women’s health, an area that has historically been underrepresented in clinical research and medical practice. A dedicated roundtable explored the latest evidence on cannabinoid-based medicines in relation to chronic pain, endometriosis, menopause, gynaecological disorders and other conditions that can significantly affect quality of life. The discussion underlined the need for patient-centred research, clinical innovation and improved care pathways.
Interactive focus groups gave delegates the opportunity to examine the practical challenges involved in producing medicinal cannabis to pharmaceutical standards. Cultivation discussions covered genetics, lighting, irrigation, nutrients, climate control, integrated pest management, automation and cultivation technologies, with an emphasis on how different disciplines can work together to improve efficiency, consistency and crop quality.
Post-harvest quality was explored in equal depth, with discussion spanning drying, curing, trimming, storage, packaging, quality control, decontamination, testing and processing. These conversations reinforced the importance of treating every stage of production as part of a connected quality system, where process control and operational discipline have a direct impact on compliance, consistency and commercial value.
The closing political debate asked whether Portugal is keeping pace with the rapidly changing cannabis policy landscape across Europe. With developments in countries such as Germany continuing to influence regional debate, the session explored what lessons Portugal can draw from other jurisdictions and how future reform might better reflect today’s scientific, clinical and regulatory realities.
The conference concluded with the VIP Sunset Networking After Party aboard the WaterX catamaran, bringing speakers, sponsors, partners and VIP attendees together for an informal evening on the Tagus River. It provided a fitting close to three days of learning, discussion and collaboration, and reflected the spirit of PTMC 2026: a forum where clinical evidence, patient experience, policy debate and industry innovation come together to help shape the future of medicinal cannabis.